Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraine, With or Without Aura Clear all
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718
View directory record Official record
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 24, 2026, 2:12 AM EDT
Not listed Phase 1Phase 2 Interventional

Treatment of Chronic Migraine Headaches.

NCT03220113
View directory record Official record
Conditions
Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions
Dexamethasone, Lidocaine, Thiamine cohort
Combination Product
Lead sponsor
Corona Doctors Medical Clinics, Inc.
Other
Eligibility
10 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Corona, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

NCT01667679
View directory record Official record
Conditions
Migraine, Headaches
Interventions
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Atogepant, Placebo-matching Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Staccato Prochlorperazine in Migraine (Out Patient)

NCT00422812
View directory record Official record
Conditions
Migraine Headache, Aura
Interventions
Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

NCT01462812
View directory record Official record
Conditions
Migraine Headache
Interventions
Sumatriptan, Placebo
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

NCT02614287
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Not applicable Interventional Results available

A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

NCT00203216
View directory record Official record
Conditions
Migraine
Interventions
levetiracetam, Transcranial Magnetic Stimulation
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Jul 24, 2026, 2:12 AM EDT
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jul 24, 2026, 2:12 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

NCT07667621
View directory record Official record
Conditions
Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions
Rimegepant, Zavegepant
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds

NCT02287376
View directory record Official record
Conditions
Migraine
Interventions
Diclofenac Potassium for Oral Solution
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety of DFN-15

NCT03009019
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine in Migraine (in Clinic)

NCT00610428
View directory record Official record
Conditions
Migraine Headache, With or Without Aura
Interventions
Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Mount Vernon, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

NCT00382993
View directory record Official record
Conditions
Migraine Disorders
Interventions
Placebo, Combination Product (sumatriptan succinate/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02828020
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
90
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

NCT06728553
View directory record Official record
Conditions
Migraine
Interventions
MTX101, Placebo
Drug
Lead sponsor
Manistee Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
7
States / cities
La Jolla, California • Santa Monica, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Evaluation of a Wearable Device for Acute Treatment of Migraines

NCT07015125
View directory record Official record
Conditions
Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 24, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study in Adult Subjects With Acute Migraines

NCT03235479
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 24, 2026, 2:12 AM EDT